Story perspectives

Revolutionary Weight Loss Treatment for Overweight Cats Under Study

12/10/2025

44 3

Summary

Story summary

OKAVA Pharmaceuticals conducts the MEOW-1 study to evaluate OKV-119, the first glucagon-like peptide-1 (GLP-1) weight loss treatment for pets.
The investigational implant aims to improve cardio-metabolic health and quality of life for overweight cats by mimicking fasting.
The study will assess safety and efficacy, and results could lead to similar research in dogs.
Preliminary evidence suggests GLP-1 drugs may treat diabetes in pets, a condition linked to rising obesity.

1 of 1

Story summary

OKAVA Pharmaceuticals conducts the MEOW-1 study to evaluate OKV-119, the first glucagon-like peptide-1 (GLP-1) weight loss treatment for pets.
The investigational implant aims to improve cardio-metabolic health and quality of life for overweight cats by mimicking fasting.
The study will assess safety and efficacy, and results could lead to similar research in dogs.
Preliminary evidence suggests GLP-1 drugs may treat diabetes in pets, a condition linked to rising obesity.